$15.600
+1.299 (+8.33%)收盘时
BLSM 同业对比
In the context of the broader market, BLSM competes directly with industry leaders such as RGNX and MPLT. With a market capitalization of $495.84M, it holds a significant position in the sector. When comparing efficiency, BLSM's gross margin of N/A stands against RGNX's 99.04% and MPLT's N/A. Such benchmarking helps identify whether BlossomHill Therapeutics Inc is trading at a premium or discount relative to its financial performance.
BlossomHill Therapeutics Inc 财务表现
The company has reported significant losses, with a net income of -23,758,000 USD for Q2 2026 and a current ratio of 5.42, indicating a strong liquidity position despite negative earnings.
Financials
FY2026Q2
YoY:
+74.93%
-24.67M
Operating Profit
FY2026Q2
YoY:
+79.39%
-23.76M
Net Income after Tax
FY2026Q2
YoY:
+81.40%
-0.78
EPS - Diluted
FY2026Q2
YoY:
+138.62%
-23.23M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。